Clinical trial preparedness in facioscapulohumeral dystrophy: Outcome measures and patient access. 8-9 April 2013, Leiden, The Netherlands.

Neuromuscular Disorders

Volumn 24, Issue 1, 2014, Pages 79-85

  Tawil, R ^a   Shaw, D W ^b   van der Maarel, S M ^c   Tapscott, S J ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUX4 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FSH HEALTH INDEX; GENE EXPRESSION PROFILING; HUMAN; INDIVIDUALIZED NEUROMUSCULAR QUALITY OF LIFE; INTERNATIONAL CLASSIFICATION OF IMPAIRMENT DISABILITY AND HEALTH; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RATING SCALE; REGISTER; SELF REPORT;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; REGISTRIES; TREATMENT OUTCOME;

EID: 84891934382     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.07.009     Document Type: Article

References (51)

1. Padberg G.W. Facioscapulohumeral disease 1982, University of Leiden, Leiden.
2. Flanigan K.M., Coffeen C.M., Sexton L., Stauffer D., Brunner S., Leppert M.F. Genetic characterization of a large, historically significant utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001, 11:525-529.
3. Tawil R., Van Der Maarel S.M. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006, 34:1-15.
4. der Maarel S.M., Tawil R., Tapscott S.J. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 2011, 17:252-258.
5. Clapp J., Mitchell L.M., Bolland D.J., et al. Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am J Hum Genet 2007, 81:264-279.
6. Gabriels J., Beckers M.C., Ding H., et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3kb element. Gene 1999, 236:25-32.
7. Lyle R., Wright T.J., Clark L.N., Hewitt J.E. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromos. Genomics 1995, 28:389-397.
8. Zeng W., de Greef J.C., Chen Y.Y., et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 2009, 5:e1000559.
9. Wallace L.M., Garwick S.E., Mei W., et al. DUX4 a candidate gene for facioscapulohumeral muscular dystrophy causes p53-dependent myopathy in vivo. Ann Neurol 2011, 69:540-552.
10. Overveld P.G., Lemmers R.J., Sandkuijl L.A., et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003, 35:315-317.
11. Kowaljow V., Marcowycz A., Ansseau E., et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 2007, 17:611-623.
12. Snider L., Geng L.N., Lemmers R.J., et al. Facioscapulohumeral dystrophy: Incomplete suppression of a retrotransposed gene. PLoS Genet 2010, 6:e1001181.
13. Lemmers R.J., van der Vliet P.J., Klooster R., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010, 329:1650-1653.
14. Dixit M., Ansseau E., Tassin A., et al. DUX4 a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 2007, 104:18157-18162.
15. Jones T.I., Chen J.C., Rahimov F., et al. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet 2012, 21:4419-4430.
16. Leidenroth A., Sorte H.S., Gilfillan G., Ehrlich M., Lyle R., Hewitt J.E. Diagnosis by sequencing: Correction of misdiagnosis from FSHD2 to LGMD2A by whole-exome analysis. Eur J Hum Genet 2012, 20:999-1003.
17. Lemmers R.J., Tawil R., Petek L.M., et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012, 44:1370-1374.
18. Mendell J.R., Csimma C., McDonald C.M., et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007, 35:8-16.
19. Tawil R., van der Maarel S., Padberg G.W., van Engelen B.G. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2010, 20:471-475.
20. [Anonymous] A prospective quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials the FSH-DY group. Neurology 1997, 48:38-46.
21. Hilbert J.E., Kissel J.T., Luebbe E.A., et al. If you build a rare disease registry will they enroll and will they use it? methods and data from the national registry of myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD). Contemp Clin Trials 2012, 33:302-311.
22. Tawil R., McDermott M.P., Mendell J.R., Kissel J., Griggs R.C. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing FSH-DY group. Neurology 1994, 44:442-446.
23. Tawil R., Figlewicz D.A., Griggs R.C., Weiffenbach B. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis FSH consortium. Ann Neurol 1998, 43:279-282.
24. Vincent K.A., Carr A.J., Walburn J., Scott D.L., Rose M.R. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007, 68:1051-1057.
25. Johnson N.E., Quinn C., Eastwood E., Tawil R., Heatwole C.R. Patient-identified disease burden in facioscapulohumeral muscular dystrophy. Muscle Nerve 2012, 46:951-953.
26. Statland J.M., McDermott M.P., Heatwole C., et al. Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2013, 23:306-312.
27. Boers M., Brooks P., Strand C.V., Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998, 25:198-199.
28. Seedat F, James MK, Rose MR. Activity rating scales in adult muscle disease: what do they actually measure? Muscle Nerve, in press.
29. Seedat F, James MK, Rose MR. Activity rating scales in adult muscle disease: how well do they actually measure? Muscle Nerve, in press.
30. Winokur S.T., Barrett K., Martin J.H., et al. Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 2003, 13:322-333.
31. Osborne R.J., Welle S., Venance S.L., Thornton C.A., Tawil R. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 2007, 68:569-577.
32. Geng L.N., Tyler A.E., Tapscott S.J. Immunodetection of human double homeobox 4. Hybridoma (Larchmt) 2011, 30:125-130.
33. Geng L.N., Yao Z., Snider L., et al. DUX4 activates germline genes retroelements and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell 2012, 22:38-51.
34. Rahimov F., King O.D., Leung D.G., et al. Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc Natl Acad Sci USA 2012, 109:16234-16239.
35. Kotelnikova E., Shkrob M.A., Pyatnitskiy M.A., Ferlini A., Daraselia N. Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in duchenne muscular dystrophy. PLoS Comput Biol 2012, 8:e1002365.
36. Nadarajah V.D., van Putten M., Chaouch A., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011, 21:569-578.
37. Ricci E., Galluzzi G., Deidda G., et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999, 45:751-757.
38. Forbes G.B., Griggs R.C., Moxley R.T., 3rd, Thornton C.T., Tawil R. K-40 and dual-energy X-ray absorptiometry estimates of lean weight compared normals and patients with neuromuscular disease. Ann N Y Acad Sci 2000, 904:111-114.
39. Skalsky A.J., Han J.J., Abresch R.T., McDonald C.M. Regional and whole-body dual-energy X-ray absorptiometry to guide treatment and monitor disease progression in neuromuscular disease. Phys Med Rehabil Clin N Am 2012, 23:67-73. x.
40. Skalsky A.J., Abresch R.T., Han J.J., Shin C.S., McDonald C.M. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2008, 18:873-880.
41. Kissel J.T., McDermott M.P., Mendell J.R., et al. Randomized double-blind placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 2001, 57:1434-1440.
42. Hollingsworth KG, de Sousa PL, Straub V, Carlier PG. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 may 2010, stockholm, sweden, 1-2 october 2009, paris, france. Neuromuscul Disord. 2012; 22 Suppl 2: S54-S67.
43. Friedman S.D., Poliachik S.L., Carter G.T., Budech C.B., Bird T.D., Shaw D.W. The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve 2012, 45:500-506.
44. Kan H.E., Klomp D.W., Wohlgemuth M., et al. Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed 2010, 23:563-568.
45. Frisullo G., Frusciante R., Nociti V., et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol 2011, 31:155-166.
46. May D.A., Disler D.G., Jones E.A., Balkissoon A.A., Manaster B.J. Abnormal signal intensity in skeletal muscle at MR imaging: patterns pearls and pitfalls. Radiographics 2000, 20 Spec No:S295-315.
47. Janeway CA Jr, Travers P., Walport M., et al. Immunobiology: the immune system in health and disease 2001, Garland Science, New York. 5th ed.
48. Tasca G., Pescatori M., Monforte M., et al. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One 2012, 7:e38779.
49. Greef J.C., Lemmers R.J., Camano P., et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010, 75:1548-1554.
50. Chen T.H., Lai Y.H., Lee P.L., et al. Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 2013, 23:298-305.
51. Brouwer O.F., Padberg G.W., Wijmenga C., Frants R.R. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 1994, 51:387-394.